A delayed complication of cancer therapy--cancer.
C. Harris
DOI: https://doi.org/10.1093/JNCI/63.2.275
1979-08-01
Journal of the National Cancer Institute
Abstract:Curing patients of cancer is the primary goal of clinical oncologists. The successful treatment of some cancers, notably Hodgkin's disease, Wilms' tumor, acut<:: lymphocytic leukemia, choriocarcinoma, and Burkitt's lymphoma, has led to an increasing number of long-term survivors. Although the acute toxicities of aggressive cancer therapy for a devastating group of diseases are well known, the delayed complications have only recently been recognized. Growth retardation, intellectual impairment, and abnormalities of the cardiovascular, excretory, endocrine, nervous, and respiratory systems are examples of these delayed complications (1, 2). Second malignant neoplasms caused by cancer therapy are also among the delayed complications. The oncogenicity of radiation used in the therapy of benign and malignant diseases has been known for several decades (3). During the last decade, the carcinogenicity of many of the .cancer chemotherapeutic drugs has become recognized in both the laboratory and the clinic (table I), and comprehensive reviews have been recently published (4-6). The most common concatenation between chemicals that are both anticancer drugs and carcinogens is the electrophilic properties of their active forms (text-fig. I). Electrophilic reactants, formed by spontaneous and/ or enzymatic activation, damage cells partly by binding to nucleophilic cellular macromolecules, including DNA. In general, drugs that bind tightly to DNA, e.g., alkylating agents, are carcinogenic, and those that do not, e.g., antimetabolites, are not carcinogenic. The cellular consequences arising from this damage are multiple. In patients with cancer, damage occurs in both neoplastic and normal cells. Lethal damage is the desired effect in neoplastic cells; however, normal cells may also be killed. If the nonlethal damage in the normal cells can be faithfully repaired, they will return to normal. If the cellular damage cannot be repaired, then malignant transformation and/or mutation may occur; the remarkable progress in the definition of the metabolic activation of chemical carcinogens, the highly stereospecific interactions with cell macromolecules, the phenotypic properties of transformed cells, and the multistage progression of the transformed cell to an invasive tumor have been recently reviewed (8, 9). The delayed complications of cancer therapy in children are especially important. These treated children have the potential of a normal life-span. Unfortunately, they may be more susceptible than are adults to the oncogenic effects of cancer chemotherapeutic agents. At a given total dose level, age at first exposure to chemical carcinogens has been shown in some cases to be an important risk factor in experimental studies and in epidemiologic investigations in